Darzalex Faspro is used to treat specific multiple myeloma patients and is also FDA-approved to treat adults with newly diagnosed light chain (AL) amyloidosis. Darzalex Faspro advantages over Darzalex are that it is faster to administer, it has less systemic administration-related reactions (ARRs)...
New Drugs Treat Rare Heart Disease Caused by Transthyretin-Mediated Amyloidosisdoi:info:doi/10.1097/01.NAJ.0000580244.26161.f0Aschenbrenner, Diane S.AJN
S100B has been observed in both Aβ plaques and in the CSF [82, 83], and overexpression of human S100B exacerbates amyloidosis and gliosis in the Tg2576 AD mouse model [84]. Likewise, mt-DNA and DNA can be released from the cells and act as DAMPs upon entering the blood circulation...
Chronologically (Fig.1), mRNA was first discovered by pioneering researches in 1961.4However, it was not until 1990 when Wolff et al. successfully expressed proteins by injecting mRNA into the body5that mRNA gradually gained recognition as a therapeutic modality.1In 1999, mRNA-engineered dendritic ...
hereditary transthyretin-mediated amyloidosis by degrading mRNA encoding transthyretin (TTR).97Thus far, six siRNA drugs have received international approval. With the ongoing development of novel chemical modifications and targeted delivery systems, more siRNA drugs are anticipated to enter the market soon...
Adjunctive treatment for patients with abnormal, viscid, or inspissated mucous secretions associated with conditions such as acute and chronic bronchopulmonary disorders (e.g., pneumonia, bronchitis, emphysema, tracheobronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis, primary amyloidosis ...
hereditary transthyretin-mediated amyloidosis by degrading mRNA encoding transthyretin (TTR).97Thus far, six siRNA drugs have received international approval. With the ongoing development of novel chemical modifications and targeted delivery systems, more siRNA drugs are anticipated to enter the market soon...
SiRNAs are now approved for use in the clinic to treat a range of diseases, are cost effective, scalable, and can be easily programmed to target any viral target in a matter of days. Despite the large number of preclinical studies that clearly show siRNAs are highly effective antivirals ...
Although multiple myeloma remains a terminal illness, the past four decades have seen a dramatic change in the outlook for a newly diagnosed patient in ter
(PD-L2) to PD-1 receptors and improves the anti-tumor response of T cells (Zhang et al.2021). Toripalimab was approved in China in 2018 to treat nasopharyngeal and urothelial carcinoma and in 2021 to treat unresectable or metastatic melanoma (Keam2019; Zhang et al.2021). In 2023, the...